The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and adolescents, Teva Pharmaceuticals announced .

Fremanezumab can now be used to treat kids ages 6 to 17 years old who weigh 45 kg (99 lbs) or more, the company said.

The calcitonin gene-related peptide (CGRP) blocker was approved for adults in 2018. Fremanezumab is the first CGRP antagonist indicated for migraine prevention in both kids and adults.

"Pediatric migraine is a complex condition that can significantly impact a child's daily life, from school performance to emotional well-being," Jennifer McVige, MD, MA, of the Dent Neurologic Institute in Buffalo, New York, said in a Teva press release.

"Having an FDA-approved treatment like Ajovy offers an importa

See Full Page